Hereditary Angioedema Patients Urge Work On Dosing, Product Shortages

Hereditary angioedema patients used the final US FDA-hosted patient-focused drug development meeting to advocate for the development of additional treatment options for HAE, citing intermittent manufacturing supply issues with existing biologics and the lack of a treatment that sufficiently prevents or controls body swelling episodes.

HAE is a rare genetic disorder that is associated with painful episodic, recurrent attacks of body swelling caused by abnormalities...